Controlling Polymorphic Impurities in Pharmaceutical Processes

  • Crystallization
  • 12 May 2026

About the webinar

In this webinar, guest speaker Jude Eames from Eurofins CDMO Alphora will share a case study on polymorphic impurities in pharmaceutical process development.

The case study highlights the importance of understanding polymorphic transitions to isolate a less thermodynamically stable polymorph. It highlights how the Crystal16 and Crystalline were utilized to diagnose problems in the process.

Polymorphic impurities can be especially problematic: often undetectable in early stages. They may only surface later in development. This leads to process redesign and costly delays.

By attending, you will:

  • Gain practical insight into hidden risks in crystallization processes
  • Understand how to identify and control trace polymorphic impurities
  • Learn strategies for building a robust, reliable crystallization process
Date: Tuesday, 12 May 2026
Time: 4.00 pm CEST  |  3.00 pm GMT  |  10.00 am EDT  |  7.00 am PDT  |  7.30 pm IST
Register now

Guest speaker

Jude Eames

Team Leader Solid-State Group at Eurofins CDMO Alphora

As a Team Leader in the Solid-State group at Eurofins CDMO Alphora, I have had the privilege of collaborating with a diverse range of clients and projects. I have over a decade of experience in characterizing materials and more than five years in pharmaceutical research. My focus is on ensuring robust processes that consistently deliver high-quality materials, overcoming unique challenges with innovative solutions. Outside of work, I enjoy spending time with my cat and playing Aussie Rules Football.